The Parker Institute for Cancer Immunotherapy has brought its 6 top centers together to support a simple initiative designed to shave months off the clinical trial process. Instead of each fielding their own IRB — institutional review board — they’ve agreed to designate one that will work for the entire network for multi-center studies.
IRBs are tasked with keeping a sharp eye on trials to preserve patient safety, oversee overall conduct and maintain data integrity. But they can also slow down the work, particularly when each of these groups field their own review boards for each study. A collective agreement to designate one IRB as the review board of record could save a considerable amount of time, these scientists agreed.